TrialAmerican journal of hematology2022

Safety and efficacy of jaktinib in the treatment of Janus kinase inhibitor-naïve patients with myelofibrosis: Results of a phase II trial.

Yi Zhang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.